Astrazeneca PLC (NYSE:AZN) – Equities researchers at Jefferies Group boosted their FY2018 earnings per share estimates for Astrazeneca PLC in a research note issued on Monday. Jefferies Group analyst J. Holford now forecasts that the company will post earnings of $1.95 per share for the year, up from their prior forecast of $1.91. Jefferies Group also issued estimates for Astrazeneca PLC’s FY2019 earnings at $2.05 EPS, FY2020 earnings at $2.36 EPS and FY2021 earnings at $2.77 EPS.

Other analysts have also recently issued reports about the stock. Piper Jaffray Companies restated a “buy” rating on shares of Astrazeneca PLC in a report on Wednesday, August 9th. Investec upgraded shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Argus restated a “buy” rating and issued a $35.00 price target on shares of Astrazeneca PLC in a report on Friday, September 1st. Natixis upgraded shares of Astrazeneca PLC from a “neutral” rating to a “buy” rating in a report on Wednesday, September 6th. Finally, Morgan Stanley cut shares of Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a report on Friday, July 28th. Four research analysts have rated the stock with a sell rating, eleven have issued a hold rating and thirteen have issued a buy rating to the company’s stock. Astrazeneca PLC currently has an average rating of “Hold” and a consensus price target of $33.60.

COPYRIGHT VIOLATION WARNING: “FY2018 EPS Estimates for Astrazeneca PLC (AZN) Increased by Analyst” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/13/fy2018-eps-estimates-for-astrazeneca-plc-azn-increased-by-analyst.html.

Shares of Astrazeneca PLC (NYSE:AZN) traded down 2.39% on Wednesday, reaching $32.62. 4,722,635 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $30.16 and a 200-day moving average price of $31.70. The company has a market cap of $82.59 billion, a PE ratio of 21.40 and a beta of 0.74. Astrazeneca PLC has a 12-month low of $25.55 and a 12-month high of $35.60.

Astrazeneca PLC (NYSE:AZN) last issued its earnings results on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.46. The business had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The business’s revenue for the quarter was down 9.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.83 earnings per share.

The firm also recently declared a None dividend, which was paid on Monday, September 11th. Shareholders of record on Friday, August 11th were given a dividend of $0.44 per share. This represents a yield of 2.98%. The ex-dividend date was Wednesday, August 9th. Astrazeneca PLC’s dividend payout ratio is presently 44.92%.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Intl Fcstone Inc. raised its position in Astrazeneca PLC by 146.9% during the 2nd quarter. Intl Fcstone Inc. now owns 32,549 shares of the company’s stock worth $1,110,000 after buying an additional 19,365 shares during the last quarter. WFG Advisors LP raised its position in Astrazeneca PLC by 36.0% during the 2nd quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after buying an additional 984 shares during the last quarter. Rikoon Group LLC raised its position in Astrazeneca PLC by 1.3% during the 2nd quarter. Rikoon Group LLC now owns 35,780 shares of the company’s stock worth $1,219,000 after buying an additional 450 shares during the last quarter. BB&T Investment Services Inc. purchased a new position in Astrazeneca PLC during the 2nd quarter worth approximately $512,000. Finally, Raymond James Financial Services Advisors Inc. raised its position in Astrazeneca PLC by 18.6% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 96,442 shares of the company’s stock worth $3,288,000 after buying an additional 15,098 shares during the last quarter. 14.18% of the stock is owned by institutional investors.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Earnings History and Estimates for Astrazeneca PLC (NYSE:AZN)

Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.